---
document_datetime: 2025-12-02 05:51:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/voydeya.html
document_name: voydeya.html
version: success
processing_time: 0.1099947
conversion_datetime: 2025-12-27 20:53:45.615926
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Voydeya

[RSS](/en/individual-human-medicine.xml/232651)

##### Authorised

This medicine is authorised for use in the European Union

danicopan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Voydeya](#news-on)
- [More information on Voydeya](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Voydeya is a medicine used in adults to treat paroxysmal nocturnal haemoglobinuria (PNH), a disease in which excessive breakdown of blood cells results in anaemia (low levels of red blood cells), thrombosis (blood clots in blood vessels), pancytopenia (low levels of blood cells) and dark urine (due to large amounts of haemoglobin - the protein in red blood cells that carries oxygen around the body - being released into the urine). Voydeya is used in addition to ravulizumab or eculizumab (other medicines for PNH) in patients who continue to have anaemia despite these treatments.

PNH is rare, and Voydeya was designated an 'orphan medicine' (a medicine used in rare diseases) on 12 December 2017. Further information on the orphan designation can be found on the [EMA website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1946) .

Voydeya contains the active substance danicopan.

Expand section

Collapse section

## How is Voydeya used?

The medicine can only be obtained with a prescription; treatment should be started by a healthcare professional experienced in the management of patients with blood-related disorders.

Voydeya is available as tablets to be taken by mouth three times a day, approximately 8 hours apart.

For more information about using Voydeya, see the package leaflet or contact your doctor or pharmacist.

## How does Voydeya work?

The complement system is a set of proteins that is part of the immune system (the body's natural defences). In patients with PNH, the complement system is overactive and damages the patients' own blood cells.

The active substance in Voydeya, danicopan, blocks a protein of the complement system called factor D. By blocking factor D, Voydeya prevents the complement system from damaging cells, thereby helping to relieve the symptoms of the disease.

## What benefits of Voydeya have been shown in studies?

Voydeya was investigated in a main study involving 86 patients with PNH who had been treated with ravulizumab or eculizumab for at least the previous 6 months and had anaemia. Patients in the study took either Voydeya or placebo (a dummy treatment) in addition to ravulizumab or eculizumab.

After 12 weeks of treatment, the haemoglobin levels in patients taking Voydeya increased on average by 2.81 g/dL, compared with an increase of 0.41 g/dL on average in patients on placebo.

## What are the risks associated with Voydeya?

For the full list of side effects and restrictions with Voydeya, see the package leaflet.

The most common side effects with Voydeya (which may affect more than 1 in 10 people) include fever, headache, increased levels of liver enzymes (a sign of possible liver problems) and pain in the extremities (arms and legs).

Based on its mechanism of action, Voydeya may increase the risk of infections. Voydeya must not be used by patients who have an ongoing infection with the bacteria *Neisseria meningitidis* , or those who are not currently vaccinated against it unless they receive antibiotics to prevent infection until 2 weeks after vaccination.

## Why is Voydeya authorised in the EU?

Voydeya in addition to ravulizumab or eculizumab was shown to be effective at reducing anaemia in patients with PNH, as shown by an increase in their haemoglobin levels after starting treatment. The safety of Voydeya is considered manageable, despite an increase in the occurrence of side effects (but not in their severity) in patients taking the medicine. The European Medicines Agency therefore decided that Voydeya's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Voydeya?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Voydeya have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Voydeya are continuously monitored. Suspected side effects reported with Voydeya are carefully evaluated and any necessary action taken to protect patients.

## Other information about Voydeya

Voydeya received a marketing authorisation valid throughout the EU on 19 April 2024.

Voydeya : EPAR - Medicine overview

Reference Number: EMA/95105/2024

English (EN) (120.14 KB - PDF)

**First published:** 17/05/2024

[View](/en/documents/overview/voydeya-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-544)

български (BG) (142.63 KB - PDF)

**First published:**

17/05/2024

[View](/bg/documents/overview/voydeya-epar-medicine-overview_bg.pdf)

español (ES) (121.53 KB - PDF)

**First published:**

17/05/2024

[View](/es/documents/overview/voydeya-epar-medicine-overview_es.pdf)

čeština (CS) (142.54 KB - PDF)

**First published:**

17/05/2024

[View](/cs/documents/overview/voydeya-epar-medicine-overview_cs.pdf)

dansk (DA) (119.74 KB - PDF)

**First published:**

17/05/2024

[View](/da/documents/overview/voydeya-epar-medicine-overview_da.pdf)

Deutsch (DE) (124.29 KB - PDF)

**First published:**

17/05/2024

[View](/de/documents/overview/voydeya-epar-medicine-overview_de.pdf)

eesti keel (ET) (119.62 KB - PDF)

**First published:**

17/05/2024

[View](/et/documents/overview/voydeya-epar-medicine-overview_et.pdf)

ελληνικά (EL) (151.75 KB - PDF)

**First published:**

17/05/2024

[View](/el/documents/overview/voydeya-epar-medicine-overview_el.pdf)

français (FR) (122.35 KB - PDF)

**First published:**

17/05/2024

[View](/fr/documents/overview/voydeya-epar-medicine-overview_fr.pdf)

hrvatski (HR) (141.17 KB - PDF)

**First published:**

17/05/2024

[View](/hr/documents/overview/voydeya-epar-medicine-overview_hr.pdf)

italiano (IT) (119.31 KB - PDF)

**First published:**

17/05/2024

[View](/it/documents/overview/voydeya-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.59 KB - PDF)

**First published:**

17/05/2024

[View](/lv/documents/overview/voydeya-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.36 KB - PDF)

**First published:**

17/05/2024

[View](/lt/documents/overview/voydeya-epar-medicine-overview_lt.pdf)

magyar (HU) (142.98 KB - PDF)

**First published:**

17/05/2024

[View](/hu/documents/overview/voydeya-epar-medicine-overview_hu.pdf)

Malti (MT) (143.95 KB - PDF)

**First published:**

17/05/2024

[View](/mt/documents/overview/voydeya-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.74 KB - PDF)

**First published:**

17/05/2024

[View](/nl/documents/overview/voydeya-epar-medicine-overview_nl.pdf)

polski (PL) (144.64 KB - PDF)

**First published:**

17/05/2024

[View](/pl/documents/overview/voydeya-epar-medicine-overview_pl.pdf)

português (PT) (122.37 KB - PDF)

**First published:**

17/05/2024

[View](/pt/documents/overview/voydeya-epar-medicine-overview_pt.pdf)

română (RO) (140.28 KB - PDF)

**First published:**

17/05/2024

[View](/ro/documents/overview/voydeya-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.52 KB - PDF)

**First published:**

17/05/2024

[View](/sk/documents/overview/voydeya-epar-medicine-overview_sk.pdf)

slovenščina (SL) (140.28 KB - PDF)

**First published:**

17/05/2024

[View](/sl/documents/overview/voydeya-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.96 KB - PDF)

**First published:**

17/05/2024

[View](/fi/documents/overview/voydeya-epar-medicine-overview_fi.pdf)

svenska (SV) (119.14 KB - PDF)

**First published:**

17/05/2024

[View](/sv/documents/overview/voydeya-epar-medicine-overview_sv.pdf)

Voydeya : EPAR - Risk management plan

English (EN) (1.01 MB - PDF)

**First published:** 17/05/2024

[View](/en/documents/rmp/voydeya-epar-risk-management-plan_en.pdf)

## Product information

Voydeya : EPAR - Product information

English (EN) (504.46 KB - PDF)

**First published:** 17/05/2024

**Last updated:** 08/07/2025

[View](/en/documents/product-information/voydeya-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-498)

български (BG) (576.43 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/bg/documents/product-information/voydeya-epar-product-information_bg.pdf)

español (ES) (539.21 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/es/documents/product-information/voydeya-epar-product-information_es.pdf)

čeština (CS) (529.91 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/cs/documents/product-information/voydeya-epar-product-information_cs.pdf)

dansk (DA) (500.88 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/da/documents/product-information/voydeya-epar-product-information_da.pdf)

Deutsch (DE) (527.77 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/de/documents/product-information/voydeya-epar-product-information_de.pdf)

eesti keel (ET) (508.92 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/et/documents/product-information/voydeya-epar-product-information_et.pdf)

ελληνικά (EL) (577.01 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/el/documents/product-information/voydeya-epar-product-information_el.pdf)

français (FR) (515.08 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/fr/documents/product-information/voydeya-epar-product-information_fr.pdf)

hrvatski (HR) (541.87 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/hr/documents/product-information/voydeya-epar-product-information_hr.pdf)

íslenska (IS) (526.06 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/is/documents/product-information/voydeya-epar-product-information_is.pdf)

italiano (IT) (503 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/it/documents/product-information/voydeya-epar-product-information_it.pdf)

latviešu valoda (LV) (527.8 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/lv/documents/product-information/voydeya-epar-product-information_lv.pdf)

lietuvių kalba (LT) (543.37 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/lt/documents/product-information/voydeya-epar-product-information_lt.pdf)

magyar (HU) (559.48 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/hu/documents/product-information/voydeya-epar-product-information_hu.pdf)

Malti (MT) (585.75 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/mt/documents/product-information/voydeya-epar-product-information_mt.pdf)

Nederlands (NL) (505.78 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/nl/documents/product-information/voydeya-epar-product-information_nl.pdf)

norsk (NO) (496.32 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/no/documents/product-information/voydeya-epar-product-information_no.pdf)

polski (PL) (577.63 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/pl/documents/product-information/voydeya-epar-product-information_pl.pdf)

português (PT) (531.46 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/pt/documents/product-information/voydeya-epar-product-information_pt.pdf)

română (RO) (561.7 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/ro/documents/product-information/voydeya-epar-product-information_ro.pdf)

slovenčina (SK) (567.78 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/sk/documents/product-information/voydeya-epar-product-information_sk.pdf)

slovenščina (SL) (533.09 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/sl/documents/product-information/voydeya-epar-product-information_sl.pdf)

Suomi (FI) (487.48 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/fi/documents/product-information/voydeya-epar-product-information_fi.pdf)

svenska (SV) (518.21 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

08/07/2025

[View](/sv/documents/product-information/voydeya-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000284950 07/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Voydeya : EPAR - All authorised presentations

English (EN) (55.55 KB - PDF)

**First published:** 17/05/2024

[View](/en/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-687)

български (BG) (75.2 KB - PDF)

**First published:**

17/05/2024

[View](/bg/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_bg.pdf)

español (ES) (54.88 KB - PDF)

**First published:**

17/05/2024

[View](/es/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_es.pdf)

čeština (CS) (62.9 KB - PDF)

**First published:**

17/05/2024

[View](/cs/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.81 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

24/10/2024

[View](/da/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (56.11 KB - PDF)

**First published:**

17/05/2024

[View](/de/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (54.39 KB - PDF)

**First published:**

17/05/2024

[View](/et/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (71.43 KB - PDF)

**First published:**

17/05/2024

[View](/el/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_el.pdf)

français (FR) (55.31 KB - PDF)

**First published:**

17/05/2024

[View](/fr/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (73.21 KB - PDF)

**First published:**

17/05/2024

[View](/hr/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.75 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

24/10/2024

[View](/is/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_is.pdf)

italiano (IT) (57.53 KB - PDF)

**First published:**

17/05/2024

[View](/it/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (70.55 KB - PDF)

**First published:**

17/05/2024

[View](/lv/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (74.21 KB - PDF)

**First published:**

17/05/2024

[View](/lt/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (72.1 KB - PDF)

**First published:**

17/05/2024

[View](/hu/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.45 KB - PDF)

**First published:**

17/05/2024

[View](/mt/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (53.13 KB - PDF)

**First published:**

17/05/2024

[View](/nl/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.4 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

24/10/2024

[View](/no/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_no.pdf)

polski (PL) (64.71 KB - PDF)

**First published:**

17/05/2024

[View](/pl/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_pl.pdf)

português (PT) (55.25 KB - PDF)

**First published:**

17/05/2024

[View](/pt/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_pt.pdf)

română (RO) (68.32 KB - PDF)

**First published:**

17/05/2024

[View](/ro/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (73.94 KB - PDF)

**First published:**

17/05/2024

[View](/sk/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (72.92 KB - PDF)

**First published:**

17/05/2024

[View](/sl/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.63 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

24/10/2024

[View](/fi/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.88 KB - PDF)

**First published:**

17/05/2024

**Last updated:**

24/10/2024

[View](/sv/documents/all-authorised-presentations/voydeya-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Voydeya Active substance Danicopan International non-proprietary name (INN) or common name danicopan Therapeutic area (MeSH)

- Hemoglobinuria, Paroxysmal
- Hemolysis

Anatomical therapeutic chemical (ATC) code L04AJ09

### Pharmacotherapeutic group

Immunosuppressants, Complement inhibitors

### Therapeutic indication

Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia

## Authorisation details

EMA product number EMEA/H/C/005517

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Alexion Europe SAS

103-105 rue Anatole France

Opinion adopted 22/02/2024 Marketing authorisation issued 19/04/2024 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Voydeya : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.41 KB - PDF)

**First published:** 08/07/2025

[View](/en/documents/procedural-steps-after/voydeya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Voydeya : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (131.52 KB - PDF)

**First published:** 27/02/2025

**Last updated:** 08/07/2025

[View](/en/documents/procedural-steps-after/voydeya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Voydeya : Orphan maintenance assessment report - initial authorisation

Adopted

Reference Number: EMA/OD/0000136076

English (EN) (427.31 KB - PDF)

**First published:** 17/05/2024

[View](/en/documents/orphan-maintenance-report/voydeya-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Voydeya : EPAR - Public assessment report

Adopted

Reference Number: EMA/107893/2024

English (EN) (7.22 MB - PDF)

**First published:** 17/05/2024

[View](/en/documents/assessment-report/voydeya-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Voydeya

Adopted

Reference Number: EMA/CHMP/63838/2024

English (EN) (131.24 KB - PDF)

**First published:** 23/02/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-voydeya_en.pdf)

#### News on Voydeya

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024) 23/02/2024

[First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria](/en/news/first-oral-treatment-against-residual-haemolytic-anaemia-patients-paroxysmal-nocturnal-haemoglobinuria) 23/02/2024

#### More information on Voydeya

- [EU/3/17/1946 - orphan designation for treatment of paroxysmal nocturnal haemoglobinuria](/en/medicines/human/orphan-designations/eu-3-17-1946)

**This page was last updated on** 08/07/2025

## Share this page

[Back to top](#main-content)